Antimicrobials effective for inhibition of enterohemorrhagic Escherichia coli strains O26, O111, and O157 and their effects on Shiga toxin releases

Journal of Microbiology and Biotechnology

Volumn 19, Issue 10, 2009, Pages 1238-1243

  Lee, John Hwa ^a   Stein, Barry D ^b  

^a Chonbuk National University   (South Korea)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Antibiotics; Cytotoxicity; EHEC; Shiga toxins

Indexed keywords

AMIKACIN; CEFAZOLIN; CEFOPERAZONE; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; SHIGA TOXIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM CULTURE; CELL COUNT; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI O111; ESCHERICHIA COLI O157; ESCHERICHIA COLI O26; INCUBATION TIME; LATEX AGGLUTINATION TEST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TOXIN ANALYSIS; VERO CELL;

ANIMALS; ANTI-INFECTIVE AGENTS; CERCOPITHECUS AETHIOPS; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; SHIGA TOXIN; VERO CELLS;

ESCHERICHIA COLI;

EID: 70849113206     PISSN: 10177825     EISSN: 17388872     Source Type: Journal    
DOI: 10.4014/jmb.0903.03006     Document Type: Article

References (20)

1. Allerberger, F., D. Rossboth, M. P. Dierich, S. Aleksic, H. Schmidt, and H. Karch. 1996. Prevalence and clinical manifestations of Shiga toxin-producing Escherichia coli infections in Austrian children. Eur. J. Clin. Microbiol. Infect. Dis. 15: 545-550.
2. Cordovez, A., V. Prado, L. Maggi, J. Cordero, J. Martinez, A. Misraji, et al. 1992. Enterohemorrhagic Escherichia coli associated with hemolytic-uremic syndrome in Chilean children. J. Clin. Microbiol. 30: 2153-2157.
3. Clinical and Laboratory Standards Institute (CLSI). 2008. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals. Approved Standard 3rd Ed. CLSI document M31-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Griffin, P. M. and R. V. Tauxe. 1991. The epidemiology of infections caused by Escherichia coli O157:H7, other enterohaemorrhagic E. coli, and the associated hemolytic uremic syndrome. Epidemiol. Rev. 13: 60-98.
5. Herold, S., J. Siebert, A. Huber, and H. Schmidt. 2005. Global expression of prophage genes in Escherichia coli O157:H7 strain EDL933 in response to norfloxacin. Antimicrob. Agents Chemother. 49: 931-944.
6. + Escherichia coli isolated from healthy and diarrheic calves. Vet. Microbiol. 66: 251-263.
7. Jeon, B., J. Jeong, G. Won, H. Park, S. Eo, H. Kang, J. Hur, and J. H. Lee. 2006. Prevalence and characteristics of Escherichia coli O26 and O111 from cattle in Korea. Int. J. Food Microbiol. 110: 123-126.
8. Jo, M., J. Kim, J. Lim, M. Kang, H. Koh, Y. Park, et al. 2004. Prevalence and characteristics of Escherichia coli O157 from major food animals in Korea. Int. J. Food Microbiol. 95: 41-49.
9. Laegreid, W. W., R. O. Elder, and J. E. Keen. 1999. Prevalence of Escherichia coli O157:H7 in range beef calves at weaning. Epidemiol. Infect. 123: 291-298.
10. Murakami, J., K. Kishi, K. Hirai, K. Hiramatsu, T. Yamasaki, and M. Nasu. 2000. Macrolides and clindamycin suppress the release of Shiga-like toxins from Escherichia coli O157:H7 in vitro. Int. J. Antimicrob. Agents 15: 103-109.
11. Ostroff, S. M., P. I. Tarr, M. A. Neill, J. H. Lewis, N. Hargrett- Bean, and J. M. Kobayashi. 1989. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J. Infect. Dis. 160: 994-999.
12. Pavia, A. T., C. R. Nichols, and P. A. Blake. 1992. Hemolyticuremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: Clinical and epidemiologic observations. J. Pediatr. 116: 544-551.
13. Prins, J. M., S. J. H. van Deventer, E. J. Kuijper, and P. Speelman. 1994. Clinical relevance of antibiotic-induced endotoxin release. Antimicrob. Agents Chemother. 38: 1211-1218.
14. Riley, L.W., R. S. Remis, S. D. Helgerson, H. B. McGee, J. G. Wells, B. R. Davis, et al. 1983. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N. Engl. J. Med. 308: 681-685.
15. Su, C. and L. J. Brandt. 1995. Escherichia coli O157:H7 infection in humans. Ann. Intern. Med. 123: 698-714.
16. Sunde, M., K. Fossum, A. Solberg, and H. Sørum. 1998. Antibiotic resistance in Escherichia coli of the normal intestinal flora of swine. Microb. Drug Resist. 4: 289-299.
17. Walterspiel, J. N., S. Ashkenazi, A. L. Morrow, and T. G. Cleary. 1992. Effect of subinhibitory concentrations of antibiotics on extracellular Shiga-like toxin 1. Infection 20: 25-29.
18. Wong, C. S., S. Jelacic, R. L. Habeeb, S. L. Watkins, and P. I. Tarr. 2000. The risk of hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N. Engl. J. Med. 342: 1930-1936.
19. Yoh, M. and T. Honda. 1997. The stimulating effect of fosfomycin, an antibiotic in common use in Japan, on the production/release of verotoxin-1 from enterohaemorrhagic Escherichia coli O157:H7 in vitro. Epidemiol. Infect. 119: 101-103.
20. Zhang, X., A. D. McDaniel, L. E. Wolf, G. T. Keusch, M. K. Waldor, and D. W. Acheson. 2000. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J. Infect. Dis. 181: 664-670.